Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07540572 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by IDEAYA Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT07540572 is a Phase 1 study that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 160 participants.
The verdict
NCT07540572, a Phase 1 study, is actively recruiting participants, sponsored by IDEAYA Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic ER+, HER2- breast cancer.
Interventions
- DRUG Fulvestrant injection
- DRUG IDE574
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-03-17 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07540572
The ClinicalTrials.gov registry entry for NCT07540572 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is IDEAYA Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant injection is the first listed.
NCT07540572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07540572 about?
NCT07540572 is a clinical study titled "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors". IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants wi...
What is the current status of trial NCT07540572?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2026-03-17. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT07540572?
The interventions under investigation include: Fulvestrant injection (DRUG), IDE574 (DRUG).
Who is sponsoring clinical trial NCT07540572?
This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.